The closing price of Protagonist Therapeutics Inc (NASDAQ: PTGX) was $27.65 for the day, down -1.50% from the previous closing price of $28.07. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 777302 shares were traded.
Ratios:
Our analysis of PTGX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 16.71 and its Current Ratio is at 16.71. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on October 30, 2023, initiated with a Overweight rating and assigned the stock a target price of $32.
On August 25, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $21.JMP Securities initiated its Mkt Outperform rating on August 25, 2022, with a $21 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 01 ’24 when PATEL DINESH V PH D sold 25,000 shares for $28.31 per share. The transaction valued at 707,750 led to the insider holds 549,590 shares of the business.
PATEL DINESH V PH D sold 30,000 shares of PTGX for $948,600 on Mar 01 ’24. The President and CEO now owns 574,590 shares after completing the transaction at $31.62 per share. On Mar 01 ’24, another insider, Ali Asif, who serves as the Chief Financial Officer of the company, sold 14,248 shares for $32.24 each. As a result, the insider received 459,318 and left with 38,397 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 1.61B and an Enterprise Value of 1.27B. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.85 while its Price-to-Book (P/B) ratio in mrq is 4.74. Its current Enterprise Value per Revenue stands at 21.17 whereas that against EBITDA is -14.06.
Stock Price History:
Over the past 52 weeks, PTGX has reached a high of $33.34, while it has fallen to a 52-week low of $13.72. The 50-Day Moving Average of the stock is 28.11, while the 200-Day Moving Average is calculated to be 21.73.
Shares Statistics:
PTGX traded an average of 746.22K shares per day over the past three months and 522.54k shares per day over the past ten days. A total of 57.71M shares are outstanding, with a floating share count of 54.78M. Insiders hold about 6.00% of the company’s shares, while institutions hold 95.61% stake in the company. Shares short for PTGX as of Mar 15, 2024 were 3.42M with a Short Ratio of 4.58, compared to 2.78M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.87% and a Short% of Float of 5.94%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of $1.19 for the current quarter, with a high estimate of $3.95 and a low estimate of -$0.62, while EPS last year was -$0.67. The consensus estimate for the next quarter is $0.34, with high estimates of $4.19 and low estimates of -$0.66.
Analysts are recommending an EPS of between $2.49 and -$2.71 for the fiscal current year, implying an average EPS of $0.75. EPS for the following year is -$0.81, with 5 analysts recommending between $2.14 and -$3.27.
